(Q45063510)

English

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

scientific article published in June 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure (English)

1 reference

Europe PubMed Central

9 December 2017

0 references

congestive heart failure

1 reference

based on heuristic

inferred from title

author name string

Cohn JN

1

1 reference

Europe PubMed Central

9 December 2017

Tognoni G

2

1 reference

Europe PubMed Central

9 December 2017

Glazer RD

3

1 reference

Europe PubMed Central

9 December 2017

Spormann D

4

1 reference

Europe PubMed Central

9 December 2017

Hester A

5

1 reference

Europe PubMed Central

9 December 2017

publication date

1 June 1999

1 reference

Europe PubMed Central

9 December 2017

Journal of Cardiac Failure

1 reference

Europe PubMed Central

9 December 2017

5

1 reference

Europe PubMed Central

9 December 2017

2

1 reference

Europe PubMed Central

9 December 2017

155-160

1 reference

Europe PubMed Central

9 December 2017

Epidemiology of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin and the remodelling of the myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac failure: a revised paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2899%2990038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1071-9164(99)90038-6

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45063510&oldid=2067466068"